Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”

Detalles Bibliográficos
Autor principal: Fukaya, Hidehira
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411187/
https://www.ncbi.nlm.nih.gov/pubmed/32782634
http://dx.doi.org/10.1002/joa3.12374
_version_ 1783568323534913536
author Fukaya, Hidehira
author_facet Fukaya, Hidehira
author_sort Fukaya, Hidehira
collection PubMed
description
format Online
Article
Text
id pubmed-7411187
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-74111872020-08-10 Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation” Fukaya, Hidehira J Arrhythm Editorial John Wiley and Sons Inc. 2020-06-02 /pmc/articles/PMC7411187/ /pubmed/32782634 http://dx.doi.org/10.1002/joa3.12374 Text en © 2020 The Authors. Journal of Arrhythmia published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Heart Rhythm Society. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Editorial
Fukaya, Hidehira
Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title_full Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title_fullStr Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title_full_unstemmed Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title_short Editorial to “Safety and Efficacy of Uninterrupted Treatment with Edoxaban or Warfarin During the Peri‐Procedural Period of Catheter Ablation for Atrial Fibrillation”
title_sort editorial to “safety and efficacy of uninterrupted treatment with edoxaban or warfarin during the peri‐procedural period of catheter ablation for atrial fibrillation”
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7411187/
https://www.ncbi.nlm.nih.gov/pubmed/32782634
http://dx.doi.org/10.1002/joa3.12374
work_keys_str_mv AT fukayahidehira editorialtosafetyandefficacyofuninterruptedtreatmentwithedoxabanorwarfarinduringtheperiproceduralperiodofcatheterablationforatrialfibrillation

Ejemplares similares